載入...
P20. The role of statins in patients with advanced NSCLC harboring KRAS mutation treated with EGFR-TKIs
BACKGROUND: Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) represent novel effective agents approved for the treatment of patients with advanced-stage non-small cell lung cancer (NSCLC). KRAS mutations have been reported as a negative prognostic and predictive factor in pati...
Na minha lista:
| 發表在: | Transl Lung Cancer Res |
|---|---|
| Main Authors: | , , , , , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
Pioneer Bioscience Publishing Company
2014
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4367782/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3978/j.issn.2218-6751.2014.AB032 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|